MediWound (MDWD) Income towards Parent Company (2013 - 2026)
MediWound (MDWD) posted quarterly Income towards Parent Company of -$7.7 million for Q4 2025, down 27.03% year-over-year from -$10.6 million in Q4 2024, and down 19.39% quarter-over-quarter from -$6.5 million in Q3 2025.
MediWound (MDWD) Income towards Parent Company (2013 - 2026) Analysis & Trends
MediWound's Income towards Parent Company history runs 13 years deep, the most recent figure standing at -$7.7 million for Q4 2025.
- In Q4 2025, Income towards Parent Company fell 27.03% year-over-year to -$7.7 million; the TTM figure through Dec 2025 stood at -$32.7 million (down 54.34% YoY), while the FY2025 annual figure was -$23.7 million, up 21.31% from the prior year.
- Income towards Parent Company for Q4 2025 stood at -$7.7 million, down from -$6.5 million in the prior quarter.
- The five-year high for Income towards Parent Company was $940000.0 in Q2 2023, with the low at -$13.2 million in Q2 2025.
- The 5-year median for Income towards Parent Company is -$4.2 million (2022), against an average of -$4.7 million.
- The sharpest annual moves came in 2023 and 2024: Income towards Parent Company soared 121.63% in 2023, then plunged 771.17% in 2024.
- MediWound's Income towards Parent Company stood at -$4.2 million in 2021, then tumbled by 76.47% to -$7.3 million in 2022, then jumped by 76.78% to -$1.7 million in 2023, then slumped by 257.61% to -$6.1 million in 2024, then decreased by 27.03% to -$7.7 million in 2025.
- Business Quant data shows MDWD's Income towards Parent Company at -$7.7 million in Q4 2025, -$6.5 million in Q3 2025, and -$13.2 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | MediWound | 170.65 Mn | 139.65 Mn | 337,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.42 Mn |
| Dec 31, 2025 | -7.73 Mn |
| Sep 30, 2025 | -6.47 Mn |
| Jun 30, 2025 | -13.24 Mn |
| Mar 31, 2025 | -5.22 Mn |
| Dec 31, 2024 | -6.08 Mn |
| Sep 30, 2024 | -5.06 Mn |
| Jun 30, 2024 | -6.31 Mn |
| Mar 31, 2024 | -3.71 Mn |
| Dec 31, 2023 | -1.70 Mn |
| Sep 30, 2023 | -2.10 Mn |
| Jun 30, 2023 | 940,000.00 |
| Mar 31, 2023 | -3.68 Mn |
| Dec 31, 2022 | -7.33 Mn |
| Sep 30, 2022 | -4.19 Mn |
| Jun 30, 2022 | -4.35 Mn |
| Mar 31, 2022 | -3.58 Mn |
| Dec 31, 2021 | -4.15 Mn |
| Sep 30, 2021 | -3.34 Mn |
| Mar 31, 2021 | -2.85 Mn |